Glyburide: caution for efficacy and fetal programming effects

American Journal of Obstetrics and Gynecology

Volumn 202, Issue 4, 2010, Pages

  Ross, Michael G ^a   Kjos, Siri L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN;

ANTHROPOMETRIC PARAMETERS; BIRTH WEIGHT; BODY COMPOSITION; DRUG EFFICACY; DRUG TRANSPORT; FETUS DISEASE; FETUS GROWTH; HIGH BIRTH WEIGHT; HUMAN; INSULIN RELEASE; INTRAUTERINE GROWTH RETARDATION; LETTER; MACROSOMIA; PREGNANCY DIABETES MELLITUS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ADIPOSE TISSUE; BIRTH WEIGHT; DIABETES, GESTATIONAL; FEMALE; FETAL DEVELOPMENT; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; PREGNANCY;

EID: 77950297656     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.09.027     Document Type: Letter

References (3)

1. Lain K.Y., Garabedian M.J., Daftary A., and Jeyabalan A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol 200 (2009) 501-506
2. Hebert M.F., Ma X., Naraharisetti S.B., et al. Are we optimizing gestational diabetes treatment with glyburide?. The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 85 (2009) 607-614
3. Plitzko D., Rumpel S., and Gottmann K. Insulin promotes functional induction of silent synapses in differentiating rat neocortical neurons. Eur J Neurosci 14 (2001) 1412-1415